- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.03. | Flagship's Empress lays off 53% of staffers in push to get science to clinic | ||
| 18.03. | Sequel Med Tech connects twiist insulin pump to Abbott's CGM ahead of market debut | ||
| 18.03. | Arch-backed HC Bioscience closes doors after seeing early data for tRNA asset | ||
| 18.03. | Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis | ||
| 18.03. | Pyxis lays off 20% of staff to swing behind single-candidate strategy | ||
| 18.03. | Kiromic furloughs 'substantially all' workers amid cash crunch, leaving 31 staff without pay | ||
| 18.03. | Nanobiotix tweaks J&J licensing deal for phase 3 cancer drug to eke out cash | ||
| 17.03. | Avidity's latest DMD data drop assuages safety concerns for RNA-based asset: analyst | ||
| 17.03. | Flagship-backed Apriori Bio lays off employees, shifts focus to pipeline development | ||
| 17.03. | Avanos taps Siemens Healthineers' Americas president as CEO | ||
| 17.03. | Curevo rounds up $110M to challenge GSK's Shringrix, nabs Moncef Slaoui to lead board | ||
| 17.03. | FDA warns hemodialysis tubing shortage could continue into autumn | ||
| 17.03. | Opko, Entera share ownership of first oral GLP-1/glucagon agonist set to enter clinic | ||
| 17.03. | Incyte posts phase 3 skin condition wins but details disappoint, sinking stock | ||
| 17.03. | Otsuka's Taiho pays $400M for Swiss partner to 'turbocharge' 3 ADCs to clinic | ||
| 17.03. | AstraZeneca goes in vivo, penning $1B deal for Belgian off-the-shelf cell therapy biotech | ||
| 17.03. | AstraZeneca's $800M rare disease bet hits primary phase 3 goal, but competitive strength still unclear | ||
| 14.03. | MicroTransponder nets $65M for stroke rehabilitation neurostimulator | ||
| 14.03. | Oligomerix small molecule tamps down tau tangles, improves coordination in mice | ||
| 14.03. | Pliant, Acelyrin resort to 'poison pills' as threat of Concentra buyout looms | ||
| 14.03. | Sutro discards CEO, 50% of staff, sole clinical-stage ADC and manufacturing site to save cash | ||
| 13.03. | George Church spinout GRObio explores strategic alternatives 6 months after $60M series B | ||
| 13.03. | Researchers identify potential MASH target after gene disruption triggers liver symptoms in mice | ||
| 13.03. | Samsung backs Alzheimer's blood test developer C2N Diagnostics with $10M | ||
| 13.03. | NIH allegedly cancels dozens of grants for vaccine hesitancy research: reports |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
